Efficacy of Antiemetic Regimens for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Patients of Breast Cancer Receiving Highly Emetogenic Chemotherapy

Abstract

Background: Chemotherapy is fraught with serious and troublesome adverse effects, of which nausea and vomiting appears earliest and is the most disturbing. Therefore, this study was planned to investigate the antiemetic drug regimens used for chemotherapy-induced nausea vomiting (CINV) in patients with breast cancer receiving highly emetogenic chemotherapy (HEC). Subjects and Methods: An observational follow-up study was conducted to assess the efficacy of antiemetic regimens in breast cancer patients receiving HEC. A total of 71 newly diagnosed patients with breast cancer were included in the study. Patients were assessed for nausea by the visual analog scale, and a history of emetic episodes and need for rescue medication were recorded at 0 h, 6 h, 24 h, 48 h, and 120 h post-chemotherapy till three cycles. Results: The patients were prescribed a combination of ondansetron and dexamethasone (n = 23, n = 17, and n = 13 in first, second, and third cycle, respectively) or a combination of aprepitant, ondansetron, and dexamethasone (n = 48, n = 54 and n = 56 in the first, second, and third cycle, respectively). The intensity of nausea was higher for the patients who were prescribed ondansetron and dexamethasone regimen as compared to patients prescribed aprepitant additionally. Complete response, i.e., no emesis and no rescue medication, was higher in triple-drug regimen (52% vs. 0.4%, 63% vs. 17.6%, and 69% vs. 23% in three cycles, respectively). Conclusion: The control of CINV was better with a combination of aprepitant, ondansetron, and dexamethasone as compared to a regimen without aprepitant.

Keywords

5-HT3 receptor antagonist - breast cancer - chemotherapy-induced nausea and vomiting - highly emetogenic chemotherapy - NK-1 receptor antagonist

• References

• 1 World Health Organization. Cancer Fact Sheet. WHO Media Centre. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. [Last acessed on 2019 May 20].
• 2 World Health Organisation. Cancer Fact Sheet India 2018. International Agency for Research on Cancer. Available from: http://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf. [Last accessed on 2019 May 14].
• 3 Salihah N, Mazlan N, Lua PL. Chemotherapy -induced nausea and vomiting: exploring patients' subjective experience. J Multidiscip Healthc 2016; 9: 145-51
• 4 Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 2013; 14: 757-66
• 5 Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA. et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017; 35: 3240-61
• 6 Navari RM. Treatment of breakthrough and refractory chemotherapy induced nausea and vomiting. Biomed Res Int 2015; 2015: 1-6
• 7 Navari RM. editor Management of Chemotherapy Induced Nausea and Vomiting: New Agents and New Uses of Current Agents. Switzerland: Springer; 2016
• 8 Alfano CM, Leach CR, Smith TG, Miller KD, Alcaraz KI, Cannady RS. et al. Equitably improving outcomes for cancer survivors and supporting caregivers: A blueprint for care delivery, research, education, and policy. CA Cancer J Clin 2019; 69: 35-49
• 9 Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?. Front Pharmacol 2018; 9: 245
• 10 Ko Y, Gwee YS, Huang YC, Chiang J, Chan A. Costs and length of stay of drug-related hospital admissions in cancer patients. Clin Ther 2014; 36: 588-92
• 11 Paul EP, Behanan A, Eapen BA, James A, Sherief SH, Palanisamy MK. et al. A study on evaluation of anti-emetics in the prevention of chemotherapy induced nausea and vomiting in cancer patients in a Tertiary Care Hospital. Indian J Pharm Pract 2017; 10: 9-16
• 12 Paul EP, Behanan A, Eapen BA, James A, Sherief SH, Palanisamy MK. et al. A study on evaluation of anti-emetics in the prevention of chemotherapy induced nausea and vomiting in cancer patients in a Tertiary Care Hospital. Indian J Pharm Pract 2017; 10: 9
• 13 Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, Bouganim N, Clemons M. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Support Care Cancer 2016; 24: 1563-9
• 14 Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F. et al. Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: Results from the pan European emesis registry study. J Pain Symptom Manage 2016; 51: 987-93
• 15 Hilarius DL, Kloeg PH, van der WallE, van den HeuvelJJ, Gundy CM, Aaronson NK. Chemotherapy -induced nausea and vomiting in daily clinical practice: A community hospital-based study. Support Care Cancer 2012; 20: 107-17
• 16 Patil VM, Noronha V, Joshi A, Ramaswamy A, Gupta S, Sahu A. et al. Adherence to and implementation of ASCO antiemetic guidelines in routine practice in a tertiary cancer center in India. J Oncol Pract 2017; 13: e574-81